

DAFTAR PUSTAKA

- Agustina, R. (2021) *Terminologi medis*. Cetakan pertama. Jawa Timur: Penerbit Qiara Media. ISBN: 978-623-555-142-5.
- American Diabetes Association (2018) ‘Standards of Medical Care in Diabetes 2018 Abridged for Primary Care Providers’, *Clinical Diabetes*, 36(1), pp. 14–37. Available at: <https://doi.org/10.2337/cd17-0119>.
- American Diabetes Association (2025) ‘Diagnosis and Classification of Diabetes: Standards of Care in Diabetes 2025’, *Diabetes Care*, 48, pp. S27–S49. Available at: <https://doi.org/10.2337/dc25-S002>.
- Azeez, T.A. and Osundina, M. (2020) ‘Insulin Resistance and Non-alcoholic Fatty Liver Disease: a Review of the Pathophysiology and The Potential Targets for Drug Actions’, *Journal of the Medical Sciences (Berkala Ilmu Kedokteran)*, 52(4). Available at: <https://doi.org/10.19106/jmedsci005204202010>.
- Barber, T.M., Kabisch, S., Pfeiffer, A.F.H. and Weickert, M.O., 2023. Metabolic-Associated Fatty Liver Disease and Insulin Resistance: A Review of Complex Interlinks. *Metabolites*, 13(6), p.757. <https://doi.org/10.3390/metabo13060757>
- Bedossa, P. and Patel, K. (2016) ‘Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease’, *Gastroenterology*, 150(8), pp. 1811-1822.e4. Available at: <https://doi.org/10.1053/j.gastro.2016.03.008>.
- Cahaya, M.R.F. dkk. (2023) *Gizi dan penyakit kronis*. Banten: Sada Kurnia Pustaka. ISBN: 978-623-838-524-9.
- Chaudhury, D. and Aggarwal, A. (2018) ‘Diabetic Dyslipidemia: Current Concepts in Pathophysiology and Management’, *Journal of Clinical and Diagnostic Research*. Journal of Clinical and Diagnostic Research, pp. OE06–OE09. Available at: <https://doi.org/10.7860/JCDR/2018/29009.11090>.
- Dinas Kesehatan Provinsi Bali (2024) *Profil Kesehatan Provinsi Bali tahun 2024*. Denpasar.
- European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) (2016) ‘EASL-EASD-EASO Clinical Practice Guidelines for The Management of Non-Alcoholic Fatty Liver Disease’, *Journal of Hepatology*, 64(6), pp. 1388–1402. <https://doi:10.1016/j.jhep.2015.11.004>.
- Fabian, R. (2023) *Gambaran Skor Fibrosis-4 (Fib-4) Pada Pasien Sirosis Hepatis Karena Hepatitis B Di RSUP Dr. Mohammad Hoesin Palembang Tahun*

2023. Palembang. Available at: <http://repository.unsri.ac.id/id/eprint/160933> (Accessed: 16 June 2025).
- Fadila, R. (2015) ‘Perbedaan Skor Penanda Fibrosis Non-Invasif Pada Penderita Sirosis Hati Dengan Dan Tanpa Diabetes Mellitus’. Available at: <http://etd.repository.ugm.ac.id> (Accessed: 16 June 2025).
- Farahmadilah, R., Rahayu, M.S. dan Zubir (2022) ‘Gambaran Derajat Fibrosis Hati Berdasarkan APRI Score dan FIB-4 Score pada Pasien Hepatitis B’, *Jurnal Kedokteran Syiah Kuala*, 22(3), pp. 1412–1026. <https://doi:10.24815/jks.v22i3.23265> .
- Fouad, Y., 2023. Metabolic-associated fatty liver disease: New nomenclature and its impact. *World Journal of Hepatology*, 15(2), pp.123–128. <https://doi.org/10.4254/wjh.v15.i2.123>
- Gunawan, S. dkk. (2023) ‘Skrining Dan Edukasi Dislipidemia Serta Perlemakan Hati Pada Komunitas Lanjut Usia’, *Communnity Development Journal*, 4(6), pp. 12119–12125. Available at: <https://journal.universitaspahlawan.ac.id/index.php/cdj/article/view/22180/16097> (Accessed: 11 July 2025).
- Hardani dkk. (2020) *Buku Metode Penelitian Kualitatif & Kuantitatif*. Yogyakarta: CV. Pustaka Ilmu. Available at: <https://www.researchgate.net/publication/340021548>.
- International Diabetes Federation (2025) ‘International Diabetes Federation Diabetes Atlas edisi ke-11 tahun 2025’.
- Jellinger, P.S. *et al.* (2017) ‘American Association Of Clinical Endocrinologists And American College Of Endocrinology Guidelines For Management Of Dyslipidemia And Prevention Of Cardiovascular Disease’, *Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists*, 23, pp. 1–87. Available at: <https://doi.org/10.4158/EP171764.APPGL>.
- Kanwal, S., 2021. Frequency of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus and its associated risk factors. *Pakistan Journal of Medical Sciences*, 37(5), pp.1360–1365. <https://doi.org/10.12669/pjms.37.5.4211>
- Katsiki N, et al. (2021). HDL and NAFLD: From pathophysiology to clinical significance. *Current Medicinal Chemistry*, 28(4), 780–795. <https://doi.org/10.2174/0929867327666200203095808> (Accessed: 24 November 2025).
- Kim, J., Ito, T., Arai, T., Atsukawa, M., Kawanaka, M., Toyoda, H., Honda, T., Yu, M.-L., Yoon, E.L., Jun, D.W., Cha, K. and Nguyen, M.H., (2024). *Modified FIB-4 Index in Type 2 Diabetes Mellitus with Steatosis: A Non-Linear*

- Predictive Model for Advanced Hepatic Fibrosis. Diagnostics*, 14(22), p.2500. <https://doi.org/10.3390/diagnostics14222500>
- Lee, J., Vali, Y., Boursier, J., Spijker, R., Anstee, Q.M., Bossuyt, P.M. and Zafarmand, M.H., (2021). Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review. *Liver International*, 41(2), pp.261–270. <https://doi:10.1111/liv.14669>.
- Lee Y, Cho Y, Lee BW, et al. (2020). Dyslipidemia and progression of nonalcoholic fatty liver disease. *Hepatology Communications*, 4(1), 66–79. <https://doi.org/10.1002/hep4.1457>
- Machali, I. (2021) *Metode Penelitian Kuantitatif Panduan Praktis Merencanakan, Melaksanakan dan Analisis dalam Penelitian Kuantitatif*. Yogyakarta: Fakultas Ilmu Tarbiyah dan Keguruan.
- Mappaware, N.A. (2016) ‘Etika dalam Penelitian kedokteran Kesehatan Universitas Muslim Indonesia’.
- Maulana, M.R. dan Kuswarini, S. (2022) ‘Analisis Risiko Kadar Enzim SGOT dan SGPT pada Penderita Diabetes Mellitus Tipe 2’, 04. Available at: <https://journals.indexcopernicus.com/api/file/viewByFileId/1506202> (Accessed: 22 July 2025).
- Moussa O, et al. (2024). Triglyceride-glucose index as a predictor of advanced fibrosis in MASLD. *BMC Gastroenterology*, 24:55. <https://doi.org/10.1186/s12876-024-03131-4> (Accessed: 24 November 2025).
- Notoatmodjo, S. (2018) *Metodologi penelitian kesehatan*. Cetakan ketiga. Jakarta: PT Rineka Cipta. ISBN: 978-979-518-984-8.
- Nusi, I.A. (2015) *Buku Ajar Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Airlangga*. 2nd edn. Edited by I. Tjokroprawiro et al. Surabaya: Airlangga University Press.
- Okada Y, et al. (2020). Association between small dense LDL cholesterol and NAFLD severity. *Journal of Clinical Lipidology*, 14(5), 689–697. <https://doi.org/10.1016/j.jacl.2020.07.006> (Accessed: 24 November 2025).
- Park, H., Yoon, E.L., Kim, M., et al. (2024) ‘Cost-effectiveness study of FIB-4 followed by transient elastography screening strategy for advanced hepatic fibrosis in a NAFLD at-risk population’, *Liver International*, 44, pp. 944–954. <https://doi:10.1111/liv.15838>
- Pasaribu, S.B., Herawati, A., Utomo, K.W. and Aji, R.H.S. (2022) *Metodologi Penelitian Untuk Ekonomi dan Bisnis*. Cetakan pertama. Banten: Media Edu Pustaka. ISBN: 978-623-99748-2-4.

- Peleg, N. *et al.* (2018) ‘Noninvasive Scoring Systems Predict Hepatic and Extra-Hepatic Cancers in Patients With Nonalcoholic Fatty Liver Disease’, *PLoS ONE*, 13(8). Available at: <https://doi.org/10.1371/journal.pone.0202393>.
- Pérez, M.J., Sánchez-Muñoz, V. and García-García, F., 2021. Visceral Adiposity and Insulin Resistance in Type 2 Diabetes Mellitus: A Pathophysiological Overview. *Diabetology & Metabolic Syndrome*, 13(1), p.56.
- PERKENI (2021) *Panduan Pengelolaan Dislipidemia di Indonesia*. Jakarta.
- PERKENI (2021) *Pedoman Pengelolaan Dan Pencegahan Diabetes Melitus Tipe 2 Dewasa Di Indonesia*. Jakarta.
- Prasetya, I.B. *et al.* (2017) *Prevalence and Profile of Fibrosis in Diabetic Patients with Non-alcoholic Fatty Liver Disease and the Associated Factors*, *Acta Med Indones-Indones J Intern Med* •. Available at: <https://actamedindones.org/index.php/ijim/article/download/365/pdf> (Accessed: 25 July 2025).
- Purba, H., Ratnasari, N. dan Pramono, B. (2023) *Prevalence And Associated Factors Of Metabolic Associated Fatty Liver Disease In Patients With Type-2 Diabetes Mellitus At Dr. Sardjito General Hospital Yogyakarta*. Available at: <https://etd.repository.ugm.ac.id/penelitian/detail/229361> (Accessed: 16 June 2025).
- Rinella, M.E., Neuschwander-Tetri, B.A., Siddiqui, M.S., Abdelmalek, M.F., Caldwell, S., Barb, D., Kleiner, D.E. and Loomba, R. (2023) ‘AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease’, *Hepatology (Baltimore, Md.)*, 77(5), pp. 1797–1835. <https://doi:10.1097/HEP.0000000000000323>
- Sakurai Y, *et al.* (2021). Oxidized LDL activates hepatic stellate cells and promotes liver fibrosis. *Scientific Reports*, 11:5804. <https://doi.org/10.1038/s41598-021-84394-y> (Accessed: 24 November 2025).
- Saragih, A.D. (2020) ‘Terapi Dislipidemia Untuk Mencegah Resiko Penyakit Jantung Koroner’, 1 (1), p. 15. Available at: <http://jurnal.globalhealthsciencegroup.com/index.php/IJNHS/article/view/32> (Accessed: 22 July 2025).
- Siregar, A.M., Tarigan, N.A. dan Sihombing, R., 2024. Korelasi TyG-BMI dengan Nilai Fibrosis (FIB-4) pada Pasien NAFLD di RSUP H. Adam Malik Medan. *Jurnal Kedokteran Klinik Tropis*, 12(1), pp.15–23.
- Sugihartono, T. dkk. (2025) *SIROSIS HATI Translasi Dari Ilmu Dasar ke Ilmu Terapan*. Surabaya: Airlangga University Press.

- Sugiyono (2020) *Metode Penelitian Kuantitatif, Kualitatif, dan R&D*. Edisi ke-2, cetakan ke-2. Bandung: Alfabeta. ISBN: 978-602-289-533-6.
- Sun DQ, et al. (2016). Low HDL and liver fibrosis: A population-based study. *Journal of Gastroenterology and Hepatology*, 31(3), 654–660. <https://doi.org/10.1111/jgh.13163> (Accessed: 24 November 2025).
- Suzuki A, et al. (2015). Small dense LDL and NAFLD severity. *Journal of Atherosclerosis and Thrombosis*, 22(8), 795–802. <https://doi.org/10.5551/jat.26947> (Accessed: 24 November 2025).
- Widiasari, K.R. dkk. (2021) *Diabetes Melitus Tipe 2: Faktor Risiko, Diagnosis, Dan Tatalaksana*, Ganesha Medicina Journal. Singaraja. Available at: <https://doi.org/10.23887/gm.v1i2.40006> (Accessed: 20 July 2025).
- World Health Organization (2016) *Global Report on Diabetes*. Geneva: World Health Organization. Available at: https://iris.who.int/bitstream/handle/10665/204871/9789241565257_eng.pdf (Accessed: 12 July 2025).
- World Health Organization (WHO), 2023. *Global Report on Diabetes*. Geneva: WHO Press.
- Yilmaz, Y. and Kaya, E., 2021. Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver. *Journal of Clinical and Translational Hepatology*, 10(2), pp.329–338. <https://doi.org/10.14218/JCTH.2021.00178>
- Younossi, Z.M., Golabi, P. and Paik, J.M., 2022. Metabolic dysfunction–associated steatotic liver disease (MASLD): New terminology and its clinical relevance. *Journal of Hepatology*, 77(5), pp.1361–1373.
- Younossi, Z.M. *et al.* (2015) ‘Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes’. Available at: <https://doi.org/10.1002/hep.28431/supinfo>.
- Zheng, Y., Ley, S.H. and Hu, F.B. (2018) ‘Global Aetiology and Epidemiology of Type 2 Diabetes Mellitus and it’s Complications’, *Nature Reviews Endocrinology*. Nature Publishing Group, pp. 88–98. Available at: <https://doi.org/10.1038/nrendo.2017.151>.
- Zheng, H., Sechi, L.A., Navarese, E.P., Casu, G. and Vidili, G., 2024. Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: A comprehensive review. *Cardiovascular Diabetology*, 23, p.346. <https://doi.org/10.1186/s12933-024-02434-5>